Evidence map›Paper›PMID 37392242›Full record

ArticleBiochemical genetics2024

The Relation of VEGFA, VEGFR2, VEGI, and HIF1A Genetic Variants and Their Serum Protein Levels with Breast Cancer in Egyptian Patients.

Amani A Abdelgalil, Rehan Monir, Mohamed Elmetwally, Maivel H Ghattas, Fagr B Bazeed, Noha M Mesbah, Dina M Abo-Elmatty, Eman T Mehanna

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Amani A AbdelgalilDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt. Amani.anwar1983@gmail.com.
Rehan MonirDepartment of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed ElmetwallyDepartment of Surgical Oncology, Oncology Center, Mansoura University, Mansoura, Egypt.
Maivel H GhattasDepartment of Medical Biochemistry, Faculty of Medicine, Port Said University, Port Said, Egypt.
Fagr B BazeedDepartment of Medical Biochemistry, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Noha M MesbahDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Dina M Abo-ElmattyDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Eman T MehannaDepartment of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia, 41522, Egypt.
Suez Canal University · EGMansoura University · EGPort Said University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most common type of cancer in Egyptian females. Polymorphisms in the angiogenesis pathway have been implicated previously in cancer risk and prognosis. The aim of the current study was to determine whether certain polymorphisms in the genes of vascular endothelial growth factor A (VEGFA), vascular endothelial growth factor receptor 2 (VEGFR2), vascular endothelial growth inhibitor (VEGI), and hypoxia-inducible factor-1α (HIF1A) associated with breast cancer development. The study included 154 breast cancer patients and 132 apparently healthy age-matched females as a control group. VEGFA rs25648 genotyping was performed using (ARMS) PCR technique; while VEGFR2 rs2071559, VEGI rs6478106, and HIF-1α rs11549465 were genotyped by the PCR-RFLP method. Serum levels of VEGF, VEGFR2, VEGI, and HIF1A proteins in breast cancer patients and controls were measured by ELISA. There was a significant association between the VEGFA rs25648 C allele and breast cancer risk (OR 2.5, 95% CI 1.7-3.6, p < 0.001). VEGFA rs25648 C/C genotype was statistically significantly higher in breast cancer patients vs. control (p < 0.001). Participants with the T/T and T/C VEGFR2 rs2071559 genotypes had 5.46 and 5 higher odds, respectively, of having breast cancer than those with the C/C genotype. For the VEGI rs6478106 polymorphism, there was a higher proportion of C allele in breast cancer patients vs. control (p = 0.003). Moreover, the C/C genotype of VEGI rs6478106 was statistically significantly higher in breast cancer patients vs. control (p = 0.001). There was no significant difference in genotypes and allele frequencies of HIF1A rs11549465 polymorphism between breast cancer cases and control individuals (p > 0.05). Serum levels of VEGFA, VEGI, and HIF1A were considerably greater in women with breast cancer than in the control (p < 0.001). In conclusion, the genetic variants VEGFA rs25648, VEGFR2 rs2071559, and VEGI rs6478106 revealed a significant association with increased breast cancer risk in Egyptian patients.

Indexed as

Breast NeoplasmsVascular Endothelial Growth Factor ABlood ProteinsCase-Control StudiesEgyptFemaleGenetic Predisposition to DiseaseGenotypeHumansHypoxia-Inducible Factor 1, alpha SubunitPolymorphism, Single NucleotideTumor Necrosis Factor Ligand Superfamily Member 15Vascular Endothelial Growth Factor Receptor-2Blood ProteinsHIF1A protein, humanHypoxia-Inducible Factor 1, alpha SubunitKDR protein, humanTNFSF15 protein, humanTumor Necrosis Factor Ligand Superfamily Member 15Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-2VEGFA protein, humanBreast cancerHIF1A rs11549465VEGFA rs25648VEGFR2 rs2071559VEGI rs6478106

Identifiers

PMID37392242
OpenAlexW4382795639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.